Over 80% of metastatic HR+/HER2− breast cancer patients now receive CDK4/6 inhibitors as first-line therapy (Goel et al., 2022; Fassl et al., 2022; Parikh et al., 2024; Jia et al., 2025). This evidence concerns the gene CDK4 and breast carcinoma.